Summary of Paysign, Inc. Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Increased by 50.8% year-over-year to $28 million, exceeding guidance.

Net Income: Rose 110% to $5.4 million, or $0.09 per diluted share, compared to $2.6 million ($0.05 per diluted share) in Q1 2025.

Adjusted EBITDA: Increased 113% to $10.6 million, with an adjusted EBITDA margin of 37.8%.

Operating Margin: Expanded to 23.8% from 13.4% year-over-year.

Gross Profit Margin: Improved to 65% from 62.9%.

Cash Position: Ended the quarter with $20.5 million in unrestricted cash and no bank debt.

2Strategic Updates and Business Highlights

Patient Affordability: Revenue grew 82% year-over-year to $15.7 million, driven by new program launches and increased claim volume.

Plasma Donor Compensation: Revenue increased 25% to $11.7 million. The company exited the quarter with 573 centers, a net increase of 89 centers year-over-year.

New Programs: Launched 4 new patient affordability programs, bringing total active programs to 135, with expectations to reach 147-150 by Q2.

Industry Engagement: Attended the Assembia Specialty Pharmacy Summit, resulting in over 50 meetings and new business opportunities.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $106.5 million and $110.5 million, representing 30% to 35% year-over-year growth.

Net Income Guidance: Projected between $13 million and $16 million, or $0.21 to $0.26 per diluted share.

Adjusted EBITDA Guidance: Expected to be between $30 million and $33 million.

Seasonality: Anticipates typical seasonal dynamics in revenue, with patient affordability peaking in Q1 and plasma revenues building through the year.

4Bad News, Challenges, or Points of Concern

Plasma Center Closures: Anticipated decline in active plasma centers to 555-560 due to the closure of 19 underperforming centers, although management expects minimal financial impact from this.

Seasonal Revenue Fluctuations: Patient affordability claims are expected to decrease after Q1, which may affect revenue consistency throughout the year.

Increased Tax Rate: Effective tax rate rose to 27.2% from 20.5% due to adjustments related to stock compensation.

5Notable Q&A Insights

Pipeline Confidence: Management indicated a balanced mix of new and existing clients contributing to future program growth, with expectations to exceed 55 net program additions.

Operational Capacity: The company is confident in its ability to handle increased program volume without additional operational constraints.

SaaS and App Development: The FDA discussions are ongoing, and the company is not yet generating revenue from its SaaS platform.

Cash Utilization: The company is holding onto its cash reserves for potential acquisitions or shareholder returns, with no immediate plans for share repurchases. Overall, Paysign reported a strong start to 2026 with significant revenue growth and improved profitability metrics, while also highlighting strategic initiatives and a robust pipeline for future growth. However, challenges remain in managing seasonal revenue fluctuations and the impact of plasma center closures.